Last updated: September 1, 2026
Fexinidazole is a strategically important but commercially small anti-infective. Sanofi markets and supplies the oral nitroimidazole for human African trypanosomiasis, primarily through public-health procurement and donation channels. Its financial value is limited by the low and declining incidence of sleeping sickness, while its public-health value is high because it replaces multi-day injectable or infusion-based regimens with a 10-day oral treatment.
The product has FDA approval for gambiense human African trypanosomiasis in adults and children weighing at least 20 kg. It has no biosimilar exposure because it is a synthetic small molecule. The principal commercial risks are low volume, dependence on international health agencies, shrinking disease prevalence, and future competition from long-acting oral agents such as acoziborole if development succeeds.
What is fexinidazole and who commercializes it?
Fexinidazole is an orally administered 5-nitroimidazole prodrug. Its active metabolites, fexinidazole sulfone and fexinidazole sulfoxide, provide activity against Trypanosoma brucei gambiense, the parasite responsible for most reported human African trypanosomiasis cases.
Sanofi is the commercial and manufacturing partner. The Drugs for Neglected Diseases initiative discovered and developed fexinidazole through a public-private partnership with Sanofi. Sanofi obtained regulatory approvals and supplies the medicine through public-health channels, while DNDi supported clinical development and access planning [1].
The product is sold or distributed under the following names:
| Market |
Product |
Sponsor or commercial partner |
Regulatory position |
| United States |
Fexinidazole tablets |
Sanofi |
FDA-approved |
| European regulatory framework |
Fexinidazole Winthrop |
Sanofi |
Positive EMA scientific opinion under Article 58 |
| Endemic African markets |
Fexinidazole tablets |
Sanofi with WHO and national programs |
Public-health deployment |
The FDA approved fexinidazole in 2021 for adults and pediatric patients at least 6 years old and weighing at least 20 kg with gambiense sleeping sickness involving both first-stage and second-stage disease [2].
What is the FDA-approved dosing and treatment position?
Fexinidazole is a fixed 10-day oral regimen taken with food:
| Patient weight |
Days 1-4 |
Days 5-10 |
| At least 35 kg |
1,800 mg once daily |
1,200 mg once daily |
| 20 kg to less than 35 kg |
1,200 mg once daily |
600 mg once daily |
The treatment eliminates the need for intravenous eflornithine-based therapy in eligible patients. Its main limitations are the requirement to take the drug with food, the need for adherence across 10 days, QT-interval prolongation risk, and restrictions in patients with certain cardiac or hepatic conditions [2].
Fexinidazole is authorized for gambiense disease. It is not a broad treatment for all forms of sleeping sickness. Rhodesiense disease, caused by Trypanosoma brucei rhodesiense, requires different treatment strategies.
How large is the fexinidazole market?
The addressable market is small in conventional pharmaceutical terms. Human African trypanosomiasis is concentrated in a limited number of African countries, with the Democratic Republic of the Congo accounting for most reported cases.
The World Health Organization reported fewer than 1,000 detected cases of human African trypanosomiasis globally in 2023, continuing a long-term decline from tens of thousands of cases annually in the early 2000s [3]. The decline reflects active screening, vector control, improved diagnostics, and expanded treatment access.
Market volume drivers
Fexinidazole demand depends on:
- Annual case detection in the Democratic Republic of the Congo and Central African Republic.
- National treatment guidelines and procurement decisions.
- WHO donation and distribution programs.
- Active surveillance in remote areas.
- Eligibility of patients by age, weight, disease stage, and clinical condition.
- The pace of global sleeping-sickness elimination programs.
The shrinking epidemiological base limits unit demand. Each diagnosed patient may require one 10-day course, but case volume is too low to support a conventional branded-drug sales model.
Geographic coverage
The commercial center of gravity is sub-Saharan Africa. The United States market has regulatory importance but limited commercial volume because sleeping sickness is rare domestically. Europe has regulatory and humanitarian relevance, but demand is also limited.
The strongest operational exposure is to:
- Democratic Republic of the Congo.
- Central African Republic.
- Guinea and other countries with historic gambiense transmission.
- WHO procurement and donation mechanisms.
What is the financial trajectory for fexinidazole?
Fexinidazole does not have a separately reported revenue line in Sanofi’s public financial disclosures. Sanofi reports revenue by broad business segment rather than by this product. The product’s financial trajectory is therefore best understood as an access-driven asset rather than a material commercial growth product [4].
| Financial factor |
Effect on fexinidazole |
| Patient population |
Structurally small and declining |
| Pricing model |
Public-health procurement and donation-oriented |
| Sales visibility |
Low; no separate public revenue disclosure |
| Gross-market opportunity |
Limited |
| Strategic value |
High for neglected-disease access and regulatory positioning |
| Commercial scalability |
Low |
| Manufacturing economics |
Dependent on sustained low-volume supply |
| Revenue volatility |
Linked to surveillance and national procurement |
Revenue exposure for Sanofi
Fexinidazole is not expected to make a material contribution to Sanofi group revenue. The product is unlikely to influence Sanofi’s earnings outlook, valuation, or segment growth independently. Its value is concentrated in:
- Maintaining supply for elimination programs.
- Meeting public-health commitments.
- Supporting Sanofi’s neglected-disease portfolio.
- Preserving manufacturing and regulatory capability for low-volume anti-infectives.
- Reducing reliance on older injectable treatments.
The principal financial risk is not patent expiry. It is demand compression caused by successful disease control. A successful elimination program reduces the number of patients requiring treatment, which also reduces product volume.
How does fexinidazole compare with competing sleeping-sickness treatments?
Fexinidazole competes primarily on administration route and operational simplicity rather than price.
| Treatment |
Administration |
Main disease position |
Commercial or operational limitation |
| Fexinidazole |
Oral, 10 days |
Gambiense disease, first and second stage |
Adherence, QT risk, weight and age restrictions |
| Pentamidine |
Injection |
Mainly first-stage gambiense disease |
Health-facility administration |
| Eflornithine plus nifurtimox, or NECT |
Intravenous plus oral |
Advanced gambiense disease |
Complex delivery and infusion requirements |
| Melarsoprol |
Intravenous |
Historically used for advanced disease |
Severe toxicity, including encephalopathic reactions |
| Suramin |
Intravenous |
Mainly rhodesiense disease |
Monitoring and parenteral administration |
| Acoziborole |
Investigational oral therapy |
Potential future gambiense treatment |
Not FDA-approved as of the cited period |
Fexinidazole’s strongest competitive advantage is that it can be administered orally in decentralized settings. That characteristic is important in rural areas where infusion capacity, trained staff, electricity, and hospital access are limited [1].
Its competitive weakness is adherence. NECT is difficult to deliver but is administered under clinical supervision. Fexinidazole depends more heavily on correct dosing and food intake over 10 days.
What patents protect fexinidazole?
Publicly available FDA materials identify the approved active ingredient, dosage form, dosing instructions, and sponsor, but they do not establish a substantial U.S. Orange Book patent estate for fexinidazole. No publicly identified patent number, expiration date, or Paragraph IV litigation is associated with the FDA approval materials cited here [2, 5].
Orange Book status
The relevant regulatory entry is the FDA-approved fexinidazole tablet product under Sanofi’s new drug application. The commercial protection profile appears materially different from that of a conventional high-revenue branded medicine:
| Protection category |
Public status |
| FDA approval |
Yes |
| New chemical entity exclusivity |
FDA approval established in 2021; statutory exclusivity period should be distinguished from patent protection |
| Orange Book patent estate |
No substantial publicly identified estate in the cited materials |
| Pediatric exclusivity |
No separate public extension established here |
| Orphan-drug exclusivity |
No clear U.S. orphan exclusivity claim established in the cited FDA approval materials |
| Paragraph IV challenges |
No publicly identified challenge |
| Biosimilar risk |
Not applicable |
| Generic risk |
Possible after applicable regulatory exclusivity and any enforceable patent rights expire |
Fexinidazole was first synthesized decades before its modern clinical development. Any original compound patent protection would not be expected to remain commercially relevant. Later patents could theoretically cover crystalline forms, formulations, manufacturing processes, or specific therapeutic uses, but the public FDA documents cited here do not establish a material blocking portfolio.
What formulations are protected by fexinidazole patents?
The FDA-approved product is an oral tablet. Public regulatory materials establish the tablet formulation and dosing regimen, but do not identify a commercially significant formulation-patent barrier. The principal technical barriers are manufacturing consistency, metabolite control, stability, packaging, and regulatory compliance rather than a clearly documented formulation monopoly.
When does fexinidazole lose exclusivity?
The FDA approved fexinidazole in 2021. For a new drug approved without a qualifying patent barrier, the key U.S. regulatory exclusivity period would generally be five years for a new chemical entity, subject to statutory details and any applicable extensions. A precise commercial generic-entry date cannot be derived solely from the public approval announcement because the operative exclusivity listing, patent records, and ANDA litigation status control actual entry.
The practical conclusion is clear: fexinidazole is unlikely to have a durable U.S. exclusivity moat comparable to a patented oncology, immunology, or rare-disease biologic. Its market is more constrained by limited patient volume and public procurement than by branded pricing power.
Which companies are challenging fexinidazole?
No publicly identified generic company has filed a high-profile Paragraph IV challenge against fexinidazole in the cited FDA and public legal materials. There is no identified U.S. patent litigation involving Sanofi and a generic challenger that materially affects launch timing.
The likely competitive pathway is ordinary generic entry after applicable FDA exclusivity and any enforceable rights, rather than litigation-led early entry. Because the market is small, generic manufacturers may have limited commercial incentive to incur development, bioequivalence, and distribution costs.
What is the biosimilar and generic risk?
Fexinidazole has no biosimilar risk because it is a chemically synthesized small molecule. It has conventional generic-drug risk.
Generic entry is commercially possible but may not rapidly transform the market. The main factors are:
- Very low patient numbers.
- Procurement concentration through governments and international agencies.
- Low expected price per treatment course.
- Need for quality-assured supply in endemic countries.
- Limited pharmacy-based distribution.
- Sanofi’s established regulatory and supply relationships.
A generic could compete on price in national tenders, but the market may be too small to support multiple competitors. In practice, supply reliability and WHO or national-program acceptance may matter more than brand recognition.
What manufacturing and intellectual-property barriers affect fexinidazole?
Fexinidazole has fewer apparent intellectual-property barriers than complex biologics or drug-device combinations. Manufacturing remains relevant because the product must meet pharmaceutical-quality standards at low volumes.
Key barriers include:
- Production of the active pharmaceutical ingredient at consistent quality.
- Control of impurities and nitroimidazole-related degradation products.
- Tablet stability under hot and humid conditions.
- Packaging suitable for distribution in tropical climates.
- Pediatric weight-based dosing requirements.
- Pharmacovigilance for QT prolongation and other adverse events.
- Regulatory registration across multiple African jurisdictions.
- Reliable forecasting as disease prevalence declines.
These barriers are operational rather than strongly exclusionary. A technically capable generic manufacturer could potentially overcome them, but the low commercial return reduces the incentive to enter.
What licensing deals shaped the fexinidazole market?
The core development arrangement was between DNDi and Sanofi. DNDi contributed neglected-disease research, development coordination, and clinical expertise. Sanofi contributed industrial development, registration, manufacturing, and supply capability [1].
The partnership was structured around access rather than a conventional premium-priced commercial launch. This model affects the financial trajectory in two ways:
- It expands availability in endemic countries.
- It limits the product’s ability to generate high-margin branded revenue.
The commercial arrangement is therefore closer to a public-health supply partnership than a conventional licensing transaction designed to maximize global net sales.
What regulatory milestones affect fexinidazole?
| Year |
Milestone |
| 2018 |
EMA scientific opinion under Article 58 supported use of fexinidazole for gambiense sleeping sickness [6] |
| 2018 |
WHO and partner programs advanced deployment planning following clinical evidence |
| 2019 |
Expanded access and national implementation began in endemic African settings |
| 2021 |
FDA approved fexinidazole tablets for gambiense human African trypanosomiasis [2] |
| 2021 onward |
Sanofi and partners continued public-health supply and pharmacovigilance activities |
The regulatory value of the FDA approval is greater than its direct revenue contribution. It gives the treatment a high level of validation and facilitates use by international health agencies and endemic-country regulators.
How strong is the fexinidazole patent estate?
The patent estate appears commercially weak relative to the estates protecting major branded medicines. The product’s defensibility rests mainly on:
- FDA and other regulatory approvals.
- Clinical evidence.
- Sanofi’s manufacturing capability.
- Public-health procurement relationships.
- Distribution infrastructure.
- Experience with neglected-disease regulatory pathways.
A weak patent estate does not necessarily mean immediate generic displacement. The low-volume market, procurement structure, and manufacturing requirements can function as practical barriers. Those barriers are less durable than enforceable composition-of-matter or formulation patents.
What generic launch scenarios exist for fexinidazole?
Base case: limited generic entry
One or a small number of quality-assured manufacturers enters after U.S. exclusivity and any relevant national protections expire. Pricing declines, but Sanofi remains an important supplier because of its WHO relationships and established manufacturing system.
Downside case: fragmented supply
Low volume discourages generic investment. Sanofi or public-health partners remain the main reliable source, while procurement depends on periodic tenders and donation commitments.
Competitive case: new oral therapy displaces fexinidazole
Acoziborole or another long-acting oral treatment reaches approval and demonstrates easier dosing, improved adherence, or broader disease-stage coverage. Fexinidazole then loses strategic importance despite retaining regulatory approval.
Elimination case: epidemiology reduces demand
Successful screening and treatment programs reduce annual cases to very low levels. Fexinidazole remains essential for residual cases and outbreak response, but sales become even less predictable.
Key Takeaways
- Fexinidazole is an FDA-approved oral treatment for gambiense human African trypanosomiasis.
- Sanofi is the principal commercial, manufacturing, and access partner.
- The product has high public-health value but low revenue potential.
- Falling sleeping-sickness incidence is the main market constraint.
- No material separately reported Sanofi revenue stream is associated with fexinidazole.
- The product has generic risk but no biosimilar risk.
- No substantial publicly identified U.S. Orange Book patent estate or Paragraph IV litigation is established in the cited materials.
- Manufacturing quality, supply reliability, and public procurement are more important barriers than patent exclusivity.
- Future oral competitors, particularly acoziborole if successfully developed, represent the main strategic threat.
- Fexinidazole is best viewed as a public-health access asset, not a conventional growth pharmaceutical.
FAQs
Is fexinidazole commercially available in the United States?
Yes. The FDA approved fexinidazole tablets for eligible patients with gambiense human African trypanosomiasis. U.S. demand is limited because the disease is rare domestically.
Does fexinidazole treat Chagas disease?
No. Fexinidazole is approved for gambiense human African trypanosomiasis and is not an approved treatment for Chagas disease.
Can fexinidazole replace melarsoprol?
Fexinidazole can reduce reliance on toxic injectable treatments in eligible gambiense patients, but it does not replace melarsoprol across all forms of sleeping sickness.
Is fexinidazole an orphan drug?
Its disease indication is rare, but the cited FDA approval materials do not establish a separate U.S. orphan-drug exclusivity period. Regulatory exclusivity must be distinguished from orphan designation.
What is the biggest long-term risk to fexinidazole sales?
The largest risk is the combination of declining sleeping-sickness incidence and future competition from simpler oral therapies. Disease elimination reduces the treatment market even when the product remains clinically valuable.
References
-
Drugs for Neglected Diseases initiative. (2018). Fexinidazole: The first all-oral treatment for sleeping sickness. https://dndi.org/research-development/portfolio/fexinidazole/
-
U.S. Food and Drug Administration. (2021). FDA approves first oral medication for treatment of sleeping sickness. https://www.fda.gov/news-events/press-announcements/fda-approves-first-oral-medication-treatment-sleeping-sickness
-
World Health Organization. (2024). Human African trypanosomiasis: Fact sheet. https://www.who.int/news-room/fact-sheets/detail/trypanosomiasis-human-african
-
Sanofi. (2023). Universal registration document and annual financial report 2023. https://www.sanofi.com/en/investors/financial-results-and-events/annual-reports
-
U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations, Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/
-
European Medicines Agency. (2018). Fexinidazole Winthrop: Article 58 opinion. https://www.ema.europa.eu/en/opinions/0000014921-divine-orphan-fexinidazole-winthrop-chmp-opinion-article-58